Next-generation antimalarial drugs: Hybrid molecules as a new strategy in drug design

Drug Development Research

Volumn 71, Issue 1, 2010, Pages 20-32

  Muregi, Francis W ^a,b   Ishih, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

Aminoquinolines; Antimalarial resistance; Malarial chemotherapy; Malarial conjugates; Trioxaquines and trioxolaquines

Indexed keywords

1,2,4 TRIOXANE DERIVATIVE; 1,4 NAPHTHOQUINONE; 3 CHLORO 6 (2 DIETHYLAMINO ETHOXY) 10 (2 DIETHYLAMINOL ETHYL) ACRIDONE; 8 AMINOQUINOLINE DERIVATIVE; ACRIDINE; ACRIDONE DERIVATIVE; AMINOACRIDINE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; DIHYDROARTEMISININ; DU 1301; ENDOPEROXIDE; FALCIPAIN 2; GLUTATHIONE; PEPTIDYL VINYL SULFONE; PIPERAQUINE; PRODRUG; QUININE; QUINOLINE; QUINOLONE; SULFONE; TRIOXAQUINE; TRIOXOLAQUINE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ARTEMISIA ANNUA; CHEMOSENSITIZATION; CINCHONA; CONJUGATE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MEGADOSE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HYBRID; MALARIA FALCIPARUM; MOLECULE; NONHUMAN; PARASITE; PATIENT COMPLIANCE; PHARMACOPHORE; REVIEW; TOXICITY;

EID: 76749095030     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20345     Document Type: Review

References (59)

1. Araújo NC, Barton V, Jones M, Stocks PA, Ward SA, Davies J, Bray PG, Shone AE, Cristiano ML, O'Neill PM. 2009. Semisynthetic and synthetic 1,2,4-trioxaquines and 1,2,4-trioxolaquines: synthesis, preliminary SAR and comparison with acridine endoperoxide conjugates. Bioorg Med Chem Lett 19:2038-2043.
2. Atamna H, Ginsburg H. 1997. The malaria parasite supplies glutathione to its host cell: investigation of glutathione transport and metabolism in human erythrocytes infected with Plasmodium falciparum. Eur J Biochem 250:670-679.
3. Barends M, Jaidee A, Khaohirun N, Singhasivanon P, Nosten F. 2007. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar J 6:81.
4. Basco LK, Dechy-Cabaret O, Ndounga M, Meche FS, Robert A, Meunier B. 2001. In vitro activities of DU-1102, a new trioxaquine derivative, against Plasmodium falciparum isolates. Antimicrob Agents Chemother 45:1886-1888.
5. Becker K, Rahlfs S, Nickel C, Schirmer RH. 2003. Glutathione: functions and metabolism in the malarial parasite Plasmodium falciparum. Biol Chem 384:551-566.
6. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitie MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L. 2008. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359:2521-2532.
7. Benoit-Vical F, Lelievre J, Berry A, Deymier C, Dechy-Cabaret O, Cazelles J, Loup C, Robert A, Magnaval JF, Meunier B. 2007. Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. Antimicrob Agents Chemother 51:1463-1472.
8. Biot C, Dessolin J, Ricard I, Dive D. 2004. Easily synthesized antimalarial ferrocene triazacyclononane quinoline conjugates. J Organomet Chem 689:4678-4682.
9. Biot C, Pradines B, Sergeant MH, Gut J, Rosenthal PJ, Chibale K. 2007. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. Bioorg Med Chem Lett 17:6434-6438.
10. Bloland PB. 2001. Drug resistance in malaria. Geneva: WHO, Malaria Epidemiology Branch, Centers for Disease Control and Prevention. p 1-23.
11. Bray PG, Martin RE, Tilley L, Ward SA, Kirk K, Fidock DA. 2005. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol 56:323-333.
12. Burgess SJ, Selzer A, Kelly JX, Smilkstein MJ, Riscoe MK, Peyton DH. 2006. A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum. J Med Chem 49: 5623-5625.
13. Capela R, Oliveira R, Goncalves LM, Domingos A, Gut J, Rosenthal PJ, Lopes F, Moreira R. 2009. Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition. Bioorg Med Chem Lett 19:3229-3232.
14. Chipeleme A, Gut J, Rosenthal PJ, Chibale K. 2007. Synthesis and biological evaluation of phenolic Mannich bases of benzaldehyde and (thio)semicarbazone derivatives against the cysteine protease falcipain-2 and a chloroquine resistant strain of Plasmodium falciparum. Bioorg Med Chem 15:273-282.
15. Chiyanzu I, Clarkson C, Smith PJ, Lehman J, Gut J, Rosenthal PJ, Chibale K. 2005. Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. Bioorg Med Chem 13:3249-3261.
16. Coslédan F, Fraisse L, Pellet A, Guillou F, Mordmuller B, Kremsner PG, Moreno A, Mazier D, Maffrand JP, Meunier B. 2008. Selection of a trioxaquine as an antimalarial drug candidate. Proc Natl Acad Sci USA 105:17579-17584.
17. Creek DJ, Charman WN, Chiu FCK, Prankerd RJ, Dong Y, Vennerstrom JL, Charman SA. 2008. Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials. Antimicrob Agents Chemother 52:1291-1296.
18. Davioud-Charvet E, Delarue S, Biot C, Schwöbel B, Boehme CC, Müssigbrodt A, Maes L, Sergheraert C, Grellier P, Schirmer RH, Becker K. 2001. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J Med Chem 44:4268-4276.
19. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, O'Neill PM, Bray PG, Ward SA, Krishna S. 2003. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424:957-961.
20. Ellis GL, Amewu R, Hall C, Rimmer K, Ward SA, O'Neill PM. 2008. An efficient route into synthetically challenging bridged achiral 1,2,4,5-tetraoxanes with antimalarial activity. Bioorg Med Chem Lett 18:1720-1724.
21. Foley M, Tilley L. 1998. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther 79:55-87.
22. Gautam A, Ahmed T, Batra V, Paliwal J. 2009. Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. Curr Drug Metab 10:289-306.
23. Gómez ZM, Rathod PK. 1990. Antimalarial activity of a combination of 5-fluoroorotate and uridine in mice. Antimicrob Agents Chemother 34:1371-1375.
24. Jones M, Mercer AE, Stocks PA, La Pensee LJ, Cosstick R, Park BK, Kennedy ME, Piantanida I, Ward SA, Davies J, Bray PG, Rawe SL, Baird J, Charidza T, Janneh O, O'Neill PM. 2009. Antitumour and antimalarial activity of artemisinin-acridine hybrids. Bioorg Med Chem Lett 19:2033-2037.
25. Kelly JX, Smilkstein MJ, Cooper RA, Lane KD, Johnson RA, Janowsky A, Dodean RA, Hinrichs DJ, Winter R, Riscoe M. 2007. Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother 51:4133-4140.
26. Kelly JX, Smilkstein MJ, Brun R, Wittlin S, Cooper RA, Lane KD, Janowsky A, Johnson RA, Dodean RA, Winter R, Hinrichs DJ, Riscoe MK. 2009. An efficient route into synthetically challenging bridged achiral 1,2,4,5-tetraoxanes with antimalarial activity. Nature 459:270-273.
27. Kouznetsov VV, Gómez-Barrio A. 2009. Recent developments in the design and synthesis of hybrid molecules based on aminoquinoline ring and their antiplasmodial evaluation. Eur J Med Chem 44:3091-3113.
28. Loup C, Lelievre J, Benoit-Vical F, Meunier B. 2007. Trioxaquines and heme-artemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine. Antimicrob Agents Chemother 51:3768-3770.
29. Maher B. 2008. Malaria: the end of the beginning. Nature 451: 1042-1046.
30. Maude RJ, Woodrow CJ, White LJ. 2010. The artemisinin antimalarials: preserving the "magic bullet." Drug Dev Res 71:12-19, (this issue).
31. Meierjohann S, Walter RD, Muller S. 2002. Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Biochem J 368:761-768.
32. Meshnick SR, Yang YZ, Lima V, Kuypers F, Kamchonwongpaisan S, Yuthavong Y. 1993. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother 37:1108-1114.
33. Morphy R, Rankovic Z. 2005. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48:6523-6543.
34. Muregi FW, Kano S, Kino H, Ishih A. 2009. Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model. Exp Parasitol 121:376-380.
35. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620.
36. Nzila A. 2006. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J Antimicrob Chemother 57:1043-1054.
37. Nzila A, Ward SA, Marsh K, Sims PF, Hyde JE. 2005. Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. Trends Parasitol 21:292-298.
38. Olliaro P, Wells TN. 2009. The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 85:584-595.
39. Olson JE, Lee GK, Semenov A, Rosenthal PJ. 1999. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg Med Chem 7:633-638.
40. Pandey AV, Tekwani BL, Singh RL, Chauhan VS. 1999. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem 274:19383-19388.
41. Perry CS, Charman SA, Prankerd RJ, Chiu FC, Dong Y, Vennerstrom JL, Charman WN. 2006. Chemical kinetics and aqueous degradation pathways of a new class of synthetic ozonide antimalarials. J Pharm Sci 95:737-747.
42. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ. 2004. Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother 48:1329-1334.
43. Rajić Z, Kos G, Zorc B, Singh PP, Singh S. 2009. Macromolecular prodrugs. XII. Primaquine conjugates: synthesis and preliminary antimalarial evaluation. Acta Pharm 59:107-115.
44. Rathod PK, Gómez ZM. 1991. Plasmodium yoelii: oral delivery of 5-fluoroorotate to treat malaria in mice. Exp Parasitol 73:512-514.
45. Rathod PK, Khatri A, Hubbert T, Milhous WK. 1989. Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 33:1090-1094.
46. Rathod PK, Leffers NP, Young RD. 1992. Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum. Antimicrob Agents Chemother 36:704-711.
47. Robert A, Meunier B. 1998. Is alkylation the main mechanism of action of the antimalarial drug artemisinin? Chem Soc Rev 27:273-279.
48. Rosenthal PJ. 2003. Antimalarial drug discovery: old and new approaches. J Exp Biol 206:3735-3744.
49. Sabbani S, Stocks PA, Ellis GL, Davies J, Hedenstrom E, Ward SA, O'Neill PM. 2008. Piperidine dispiro-1,2,4-trioxane analogues. Bioorg Med Chem Lett 18:5804-5808.
50. Sajid M, McKerrow JH. 2002. Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 120:1-21.
51. Solomon VR, Haq W, Smilkstein M, Srivastava K, Rajakumar S, Puri SK, Katti SB. 2008. Synthesis and antimalarial activity of novel side chain modified antimalarial agents derived from 4-aminoquinoline. Med Chem 4:446-456.
52. Uhlemann AC, Wittlin S, Matile H, Bustamante LY, Krishna S. 2007. Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277). Antimicrob Agents Chemother 51:667-672.
53. Vangapandu S, Sachdeva S, Jain M, Singh S, Singh PP, Kaul CL, Jain R. 2003. 8-quinolinamines and their pro prodrug conjugates as potent blood-schizontocidal antimalarial agents. Bioorg Med Chem 11:4557-4568.
54. Van Schalkwyk DA, Egan TJ. 2006. Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug Resist Updat 9:211-226.
55. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN. 2004. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430:900-904.
56. Wang X, Dong Y, Wittlin S, Creek D, Chollet J, Charman SA, Tomas JS, Scheurer C, Snyder C, Vennerstrom JL. 2007. Spiroand dispiro-1,2-dioxolanes: contribution of iron(II)-mediated oneelectron vs two-electron reduction to the activity of antimalarial peroxides. J Med Chem 50:5840-5847.
57. Wei N, Sadrzadeh SM. 1994. Enhancement of hemin-induced membrane damage by artemisinin. Biochem Pharmacol 48: 737-741.
58. Wiwanitkit V. 2006. Plasmodium and host glutathione reductase: molecular function and biological process. Afr J Biotechnol 5:2009-2013.
59. Zhou L, Alker A, Ruf A, Wang X, Chiu FC, Morizzi J, Charman SA, Charman WN, Scheurer C, Wittlin S, Dong Y, Hunziker D, Vennerstrom JL. 2008. Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277. Bioorg Med Chem Lett 18:1555-1558.